Good. Why should MRNA get 10% of their market cap in free government research handouts when there's other pharmaceutical companies that have been far more successful at making vaccines. MRNA literally has two products.
This is a dying one trick pony, the ultimate COVID meme stock, that has lost 95% of its peak market capitalization. One of the top 15 or so pharma companies will probably buy them out when the market cap gets to $3-5B.
JumpCrisscross · 18h ago
> Why should MRNA get 10% of their market cap in free government research handouts
There is a muted commercial incentive to develop vaccines for potential pandemics. There is great public interest, however, in not being the country or trading bloc that forgot to.
(Not saying that’s worth almost $1bn/year, though.)
> This is a dying one trick pony
Not a domain expert. But Moderna’s pipeline [1] seems decently varied.
> One of the top 15 or so pharma companies will probably buy them out when the market cap gets to $3-5B
This is a dying one trick pony, the ultimate COVID meme stock, that has lost 95% of its peak market capitalization. One of the top 15 or so pharma companies will probably buy them out when the market cap gets to $3-5B.
There is a muted commercial incentive to develop vaccines for potential pandemics. There is great public interest, however, in not being the country or trading bloc that forgot to.
(Not saying that’s worth almost $1bn/year, though.)
> This is a dying one trick pony
Not a domain expert. But Moderna’s pipeline [1] seems decently varied.
> One of the top 15 or so pharma companies will probably buy them out when the market cap gets to $3-5B
Agree.
[1] https://www.modernatx.com/en-US/research/product-pipeline